Zobrazeno 1 - 5
of 5
pro vyhledávání: '"James G. Kublin"'
Autor:
Shirley Galbiati, Jessie K. Kennedy, Thomas L. Richie, Stephen L. Hoffman, Natasha Kc, Lisa A. Jackson, Sumana Chakravarty, Eric R. James, Yonas Abebe, B. Kim Lee Sim, James G. Kublin, Sean C. Murphy, Kristen W. Cohen, Gregory A. Deye
Publikováno v:
PLoS Pathogens, Vol 17, Iss 5, p e1009594 (2021)
PLoS Pathogens
PLoS Pathogens
PfSPZ-CVac combines ‘PfSPZ Challenge’, which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x104 PfSPZ-CVac given 28
Autor:
Lamar Ballweber Fleming, Craig Innes, Valentin Voillet, Lindsay N. Carpp, Anneta F Naidoo, M. Juliana McElrath, Peter B. Gilbert, Glenda Gray, Guido Ferrari, Nicole Grunenberg, Linda-Gail Bekker, Fatima Laher, Georgia D. Tomaras, Erica Andersen-Nissen, James G. Kublin, Ying Huang, Andrew Fiore-Gartland, Michael S. Harper
Publikováno v:
PLoS Pathogens
PLoS Pathogens, Vol 17, Iss 3, p e1009363 (2021)
PLoS Pathogens, Vol 17, Iss 3, p e1009363 (2021)
The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predic
Autor:
Jetta Garrity, Brittany R. Carey, Peter T. Hraber, Michael Hoelscher, Merlin L. Robb, James G. Kublin, Bette T. Korber, M. Juliana McElrath, Ronald Swanstrom, Nancy Tumba, Alexander. Robles, David C. Montefiori, Ruwayhida Thebus, Carolyn Williamson, Daniel J. Sheward, Haili Tang, Lynn Morris, Jerome H. Kim, Joseph Makhema, Keren Middelkoop, Thabo Diphoko, Leonard Maboko, Jinny C. Marais, Beatrice H. Hahn, Quarraisha Abdool Karim, Kshitij Wagh, Hongmei Gao, Cecilia Rademeyer, Glenda E. Gray, Salim S. Abdool Karim, Feng Gao, Kelli Greene, Linda-Gail Bekker, Penny L. Moore, Marion Vermeulen, Gama Bandawe, Michael S. Seaman, Elena E. Giorgi
Publikováno v:
PLoS Pathogens
PLoS One
PLoS Pathogens, Vol 12, Iss 7, p e1005742 (2016)
PLoS One
PLoS Pathogens, Vol 12, Iss 7, p e1005742 (2016)
The development of biomedical interventions to reduce acquisition of HIV-1 infection remains a global priority, however their potential effectiveness is challenged by very high HIV-1 envelope diversity. Two large prophylactic trials in high incidence
Autor:
Sean C Murphy, Gregory A Deye, B Kim Lee Sim, Shirley Galbiati, Jessie K Kennedy, Kristen W Cohen, Sumana Chakravarty, Natasha Kc, Yonas Abebe, Eric R James, James G Kublin, Stephen L Hoffman, Thomas L Richie, Lisa A Jackson
Publikováno v:
PLoS Pathogens, Vol 17, Iss 5, p e1009594 (2021)
PfSPZ-CVac combines 'PfSPZ Challenge', which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis. In a previously-published PfSPZ-CVac study, three doses of 5.12x104 PfSPZ-CVac given 28 days
Externí odkaz:
https://doaj.org/article/38a4f864bb53428093ed8cf2eb54e63e
Autor:
Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N Carpp, Anneta F Naidoo, Michael S Harper, Valentin Voillet, Nicole Grunenberg, Fatima Laher, Craig Innes, Linda-Gail Bekker, James G Kublin, Ying Huang, Guido Ferrari, Georgia D Tomaras, Glenda Gray, Peter B Gilbert, M Juliana McElrath
Publikováno v:
PLoS Pathogens, Vol 17, Iss 3, p e1009363 (2021)
The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predic
Externí odkaz:
https://doaj.org/article/5a0b9dc7456e43099784dfcec3d30a7c